The lancet oncology
-
Treatment for non-small-cell lung cancer is evolving from the use of cytotoxic chemotherapy to personalised treatment based on molecular alterations. This past decade has witnessed substantial progress in the treatment of patients with EGFR mutations and ALK rearrangements, and it is now possible to study complex genomic alterations in cancer using next-generation sequencing. ⋯ These data clearly suggest that lung adenocarcinoma is associated with distinct genomic alterations compared with other lung cancer subtypes, and highlight the widespread molecular heterogeneity that underlies the disease. In this Review, we discuss some of the key findings from genomic studies of lung adenocarcinoma.
-
The lancet oncology · Jul 2015
Comparative Study Clinical TrialLocal radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial.
An abscopal response describes radiotherapy-induced immune-mediated tumour regression at sites distant to the irradiated field. Granulocyte-macrophage colony-stimulating factor is a potent stimulator of dendritic cell maturation. We postulated that the exploitation of the pro-immunogenic effects of radiotherapy with granulocyte-macrophage colony-stimulating factor might result in abscopal responses among patients with metastatic cancer. ⋯ New York University School of Medicine's Department of Radiation Oncology and Cancer Institute.
-
The lancet oncology · Jul 2015
Randomized Controlled Trial Multicenter StudyTAS-102 for metastatic refractory colorectal cancer.
-
The lancet oncology · Jul 2015
Randomized Controlled TrialMismatch repair deficiency predicts benefit of anti-PD-1 therapy.
-
The lancet oncology · Jul 2015
Randomized Controlled Trial Comparative StudyCombination immunotherapy breakthrough for melanoma.